> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 5.4% Of Novavax As Partner Payments Help Narrow Its Losses
- URL: https://www.bullished.co/state-street-holds-5-4-of-novavax-as-partner-payments-help-narrow-its-losses-dbb60cdf/
- Published: 2026-11-10T14:22:01.000Z
- Updated: 2026-11-10T14:22:01.000Z
- Description: The passive holding covered 8,827,707 shares, while Novavax's path to adjusted profitability depends on partner product launches.
- Author: Matteo Parrino
- Tags: SEC Filings, NVAX, Industry: Healthcare

State Street held a [5.4% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000697/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Novavax](https://www.bullished.co/tag/nvax/), which develops protein-based vaccines and the Matrix-M immune-response ingredient, according to a passive ownership disclosure filed Tuesday. The position covered 8,827,707 common shares as of September 30, while partner payments helped the vaccine company narrow its losses.

## A Stake Without A Control Push

State Street certified that its holding arose from ordinary business activity, rather than an effort to change or influence control of Novavax.

The investor had [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000697/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 8,362,217 shares and sole voting power over none. It reported shared power to dispose of all 8,827,707 shares.

Novavax had a market value of $1.8 billion as of 9:16 a.m. ET Tuesday.

## Sanofi's $125 Million Payoff

Novavax's Sanofi partnership delivered a $125 million milestone payment when a late-stage trial of a combined influenza/COVID-19 vaccine triggered the payment. Novavax raised its full-year revenue outlook after receiving the money.

Its third-quarter net loss narrowed to $31 million from $202 million a year earlier. Those results sit against revenue declines and continuing losses; its five-year total shareholder return fell 93.65%.

Sanofi now leads commercialization of Nuvaxovid, Novavax's COVID-19 vaccine, which is authorized by the U.S. FDA, the European Commission and several other countries.

## Matrix-M And The Launch Dependency

Novavax earns money from licensing and supplying Matrix-M to partners including Sanofi, Pfizer, Takeda and Serum Institute of India, as well as selling COVID-19 doses under government supply agreements. It produces Matrix-M in Uppsala, Sweden.

The ingredient strengthens the immune response to a vaccine. It also forms part of the R21/Matrix-M malaria vaccine, available in 24 countries as of February 2026\. Novavax is conducting early-stage research in shingles and C. diff.

Jim Kelly, Novavax's chief financial officer, said the company expects to cut adjusted research, development, selling and administrative expenses by [over $200 million](https://finance.yahoo.com/healthcare/articles/nvax-q3-2026-deep-dive-130136291.html?.tsrc=rss&ref=bullished.co) by 2028.

Management said adjusted profitability depends on successful commercial launches of partner products. Those launches remain central to Novavax's effort to move beyond its losses.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: NOVAVAX INC (NVAX)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000697/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook](https://finance.yahoo.com/healthcare/articles/nvax-q3-2026-deep-dive-130136291.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Novavax (NVAX) stock trades up, here is why](https://finance.yahoo.com/markets/stocks/articles/novavax-nvax-stock-trades-why-064536035.html?ref=bullished.co) — Yahoo Finance
- [Novavax (NVAX) Looks Cheap After Sanofi Milestone And Stronger Q3 Results](https://finance.yahoo.com/healthcare/articles/novavax-nvax-looks-cheap-sanofi-161045875.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Novavax Inc. (NASDAQ:NVAX) : Articles :: Law360](https://www.law360.com/companies/novavax-inc/articles?article%5Frelated%5Fcontent=1&ref=bullished.co) — law360.com
- [Novavax Inc. (NASDAQ:NVAX) : Cases :: Law360](https://www.law360.com/companies/novavax-inc/cases?ref=bullished.co) — law360.com

### More on Novavax

- [Novavax Resets Its Profitability Timing Around Sanofi's 2029 U.S. Flu-COVID Launch Target](https://www.bullished.co/novavax-resets-its-profitability-timing-around-sanofis-2029-u-s-flu-covid-launch-target-fd8f7eac/)
- [Novavax Earns $125 Million From Sanofi After Fifth Patient Is Dosed In Flu-COVID Trial](https://www.bullished.co/novavax-earns-125-million-from-sanofi-after-fifth-patient-is-dosed-in-flu-covid-trial-a244869d/)
- [Novavax Holder Himanshu Shah Says His 6.46% Stake No Longer Aims To Influence Control](https://www.bullished.co/novavax-holder-himanshu-shah-says-his-6-46-stake-no-longer-aims-to-influence-control-79ec8a24/)

[All Novavax (NVAX) coverage →](https://www.bullished.co/tag/nvax/)